Table 1 Patient characteristics.

From: Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

 

Patients (n = 75)

Age

 

 Median, y

63

 Range

26–87

Gender

 

 Male

50 (67%)

 Female

25 (33%)

Histology

 

 Clear cell

56 (75%)

 Other

13 (17%)

 Undetermined

6 (8%)

Prior nephrectomy

 

 No

16 (21%)

 Yes

59 (79%)

Fuhrman grade

 

 G1-G2

14 (19%)

 G3-G4

32 (42%)

 Undetermined

29 (39%)

ECOG performance status

 

 0

28 (37%)

 1

38 (51%)

 2

9 (12%)

Number of metastatic sites

 

< 2

33 (44%)

> 2

42 (56%)

Platelets

 

< 400000

61 (81%)

> 400000

13 (17%)

 Undetermined

1 (1%)

MSKCC score

 

 Favourable

2 (2%)

 Intermediate

51 (68%)

 Poor

17 (23%)

 Undetermined

5 (7%)

  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan-Kettering Cancer Center.
Back to article page